After years of limited options for one of the most debilitating symptoms of primary biliary cholangitis, relief may finally be within reach. The FDA is expected to decide by March 24, 2026, whether to approve linerixibat, a first-in-class oral medication developed by GSK that specifically targets the severe, unrelenting itching — known as cholestatic pruritus — that plagues many PBC patients. If approved, linerixibat would become only the fourth FDA-approved therapy for PBC, and notably the first designed to treat the itch itself rather than slow the underlying liver disease. This potential approval comes during a period of unusual activity in the PBC treatment landscape.
In 2024, two new drugs received accelerated FDA approval for the first time in years: elafibranor (Iqirvo) in June and seladelpar (Livdelzi) in August. Meanwhile, obeticholic acid (Ocaliva), once considered a breakthrough, was pulled from the U.S. market in late 2025 after reports of serious liver injury. For the estimated 105,506 American adults living with PBC — a disease that disproportionately affects women — this shifting drug landscape represents both new hope and hard lessons about the gap between approval and long-term safety. This article examines where linerixibat stands, what the clinical trial data actually shows, how recent approvals and withdrawals have reshaped the treatment picture, and what PBC patients and their caregivers should understand as these changes unfold.
Table of Contents
- What Is Linerixibat, and Why Has This PBC Drug Taken So Long to Reach Approval?
- The GLISTEN Trial Results — What the Numbers Tell Us and What They Don’t
- How the 2024 Drug Approvals Changed the PBC Landscape
- What the Ocaliva Withdrawal Means for PBC Patients and Treatment Decisions
- Living With PBC — Why Pruritus Is More Than Just an Itch
- The Current PBC Treatment Toolkit — What Remains After Ocaliva’s Exit
- What Comes Next for PBC Treatment
- Conclusion
- Frequently Asked Questions
What Is Linerixibat, and Why Has This PBC Drug Taken So Long to Reach Approval?
Linerixibat is an ileal bile acid transporter (IBAT) inhibitor, a class of drug that works by blocking the reabsorption of bile acids in the gut. In PBC, the liver‘s bile ducts are progressively destroyed by the immune system, causing bile acids to accumulate in the bloodstream. That accumulation is what drives the maddening, sleep-destroying itch that many patients describe as worse than the disease itself. Unlike existing PBC therapies that aim to protect liver function, linerixibat was designed from the start to go after the pruritus directly — a distinction that matters enormously to the people living with it. The road to this point has not been short. GSK’s Phase III GLISTEN trial enrolled 238 PBC patients with cholestatic pruritus, randomizing them equally between linerixibat and placebo.
Over 24 weeks, patients on linerixibat experienced a statistically significant reduction in their monthly itch scores compared to placebo, with an adjusted mean difference of −0.72 (95% CI −1.15 to −0.28; p=0.0013). Those numbers may sound modest on paper, but for patients who have spent years scratching themselves raw with no pharmaceutical recourse, any measurable relief represents a genuine shift. Marketing applications are also under review in the EU, UK, China, and Canada, signaling that this is not just an American story. The timing of the expected approval is also notable for another reason. In March 2026, GSK licensed worldwide rights for linerixibat to Alfasigma in a deal worth up to $690 million — $300 million upfront, with an additional $100 million triggered upon FDA approval. That kind of financial commitment from a specialty pharma company suggests real confidence in the drug’s commercial future, though it also raises questions about eventual pricing and patient access.
The GLISTEN Trial Results — What the Numbers Tell Us and What They Don’t
The GLISTEN trial (NCT04950127) was a double-blind, randomized, placebo-controlled study, the gold standard design for establishing efficacy. The primary endpoint — reduction in monthly itch score over 24 weeks — was met with statistical significance. But clinical significance and statistical significance are not always the same thing, and patients deserve an honest accounting of both. A mean itch score reduction of 0.72 points more than placebo is meaningful in a condition where existing treatments offer essentially nothing for pruritus, but it also means that not every patient in the trial experienced dramatic relief. Some responded well; others less so. This is a pattern common across drugs targeting subjective symptoms like itch or pain, where individual variation is enormous.
However, if you are a patient whose pruritus has been inadequately controlled — or completely uncontrolled — the prospect of even partial relief should not be dismissed. The safety profile requires candid discussion. Gastrointestinal side effects were common: 61% of patients on linerixibat experienced diarrhea compared to 18% on placebo, and abdominal pain occurred in 18% versus 3%. Treatment discontinuations due to GI events ran at 7% for linerixibat versus less than 1% for placebo. For some patients, trading severe itch for significant diarrhea may feel like swapping one misery for another. This is a conversation that will need to happen honestly between patients and their hepatologists, weighing which symptom burden is more tolerable on a case-by-case basis.
How the 2024 Drug Approvals Changed the PBC Landscape
The PBC treatment world was remarkably static for decades. Ursodeoxycholic acid (UDCA) remained the lone FDA-approved option for years, and while it slows disease progression in many patients, roughly 40% either do not respond adequately or cannot tolerate it. Then, within the span of two months in 2024, two new drugs broke through. Elafibranor (Iqirvo), developed by Ipsen, received accelerated FDA approval on June 10, 2024. It is a first-in-class peroxisome proliferator-activated receptor (PPAR) agonist indicated for PBC patients with inadequate response to UDCA or who cannot tolerate it. The approval was based on the Phase III ELATIVE trial, which enrolled 161 patients over 52 weeks.
Then on August 14, 2024, Gilead’s seladelpar (Livdelzi), a selective PPARδ agonist, also received accelerated approval. The Phase III RESPONSE trial showed that 62% of patients achieved a composite biochemical response at 12 months versus 20% on placebo, and 25% achieved alkaline phosphatase (ALP) normalization at month one. Seladelpar also received EU conditional marketing authorization in 2025. Both approvals carry an important caveat that patients need to understand: they were granted under the FDA’s accelerated approval pathway, meaning the surrogate endpoints used — biochemical markers like ALP — are believed to predict clinical benefit but have not yet been confirmed to improve survival or prevent liver decompensation. Confirmatory trials are still required. This is not a reason to avoid these drugs, but it is a reason to maintain realistic expectations and continued monitoring.
What the Ocaliva Withdrawal Means for PBC Patients and Treatment Decisions
The withdrawal of obeticholic acid (Ocaliva) from the U.S. market serves as a sobering reminder that drug approval is not the final word on safety. On September 11, 2025, Intercept Pharmaceuticals announced a voluntary withdrawal following an FDA request. The drug was officially removed from commercial availability on November 14, 2025. The reasons were serious. The FDA identified 20 cases of significant liver injury occurring between May 2021 and September 2024, including 7 liver transplants, 8 transplant evaluations or listings, and 6 liver-related deaths. What made these cases particularly alarming was that some occurred in non-cirrhotic patients — people who had no pre-existing severe liver damage.
The FDA also placed all clinical trials of obeticholic acid on hold. For patients who had been taking Ocaliva, the withdrawal created an urgent need to transition to alternative therapies, a process complicated by the limited number of approved options. The Ocaliva story illustrates a broader tradeoff in PBC drug development. Accelerated approval pathways get drugs to patients faster, which is critical for a disease with so few treatment options. But the post-marketing surveillance period is where the true safety picture emerges. Patients starting any newly approved PBC therapy — whether elafibranor, seladelpar, or potentially linerixibat — should discuss with their doctors what monitoring looks like and what warning signs to watch for. The benefit of new treatments is real, but so is the need for vigilance.
Living With PBC — Why Pruritus Is More Than Just an Itch
For people unfamiliar with PBC, it can be difficult to grasp why a drug that targets itching would warrant this level of attention. Cholestatic pruritus is not a minor nuisance. It is a relentless, whole-body sensation that worsens at night, resists conventional anti-itch treatments, disrupts sleep for months and years, and drives some patients to the point of psychological crisis. Surveys of PBC patients consistently rank pruritus among the symptoms that most severely impairs quality of life, sometimes above fatigue and even the fear of liver failure itself. Until now, the medical options for PBC-related pruritus have been limited to off-label use of drugs like cholestyramine, rifampicin, and naltrexone — none of which were developed for this condition, and none of which work reliably.
If linerixibat is approved, it will be the first therapy specifically designed and tested for cholestatic pruritus in PBC. However, patients should be aware that the GLISTEN trial excluded individuals with decompensated liver disease, so the drug’s safety and efficacy in more advanced PBC remains uncertain. The connection to brain health and cognitive function is also worth noting for readers of this site. Chronic sleep disruption from severe pruritus has well-documented effects on cognitive performance, mood regulation, and overall neurological wellbeing. For older PBC patients, particularly women over 60 who represent a significant portion of the PBC population, the compounding effects of sleep deprivation on an aging brain are not trivial. Addressing pruritus is not just about skin-deep comfort — it has downstream implications for mental clarity and quality of life.
The Current PBC Treatment Toolkit — What Remains After Ocaliva’s Exit
With Ocaliva withdrawn, only three FDA-approved agents remain for PBC: UDCA, elafibranor (Iqirvo), and seladelpar (Livdelzi). If linerixibat clears its March 24 PDUFA date, it would become the fourth — but with a fundamentally different purpose. UDCA, elafibranor, and seladelpar all target disease progression by improving liver biochemistry. Linerixibat targets symptom relief.
A patient with both inadequate biochemical response and severe pruritus might, in theory, benefit from a combination approach, though such combination strategies have not been formally tested in large trials. PBC disproportionately affects women, with an adjusted prevalence of approximately 58 per 100,000 women compared to about 15 per 100,000 men. The total U.S. prevalence is estimated at 40.9 per 100,000 persons, or roughly 105,506 adults based on 2021 data. These numbers may undercount the true burden, as PBC is frequently underdiagnosed, particularly in primary care settings where abnormal liver enzymes may be attributed to more common conditions.
What Comes Next for PBC Treatment
The next twelve months could reshape PBC care more than the previous two decades combined. If linerixibat is approved, the immediate focus will shift to real-world access: insurance coverage, pricing under the Alfasigma licensing deal, and whether patients outside major hepatology centers can actually get the drug prescribed. The EU, UK, Chinese, and Canadian regulatory decisions will follow, potentially expanding global access. Longer term, the confirmatory trials required for elafibranor and seladelpar will be closely watched.
If those drugs demonstrate not just biochemical improvement but actual prevention of liver decompensation or improved survival, it would validate the accelerated approval pathway for PBC and likely encourage further investment in the space. If they do not, the field will face difficult questions. For now, though, the direction is cautiously encouraging. After decades of near-total therapeutic stagnation, PBC patients finally have options — imperfect, still-emerging options, but options nonetheless.
Conclusion
The PBC drug landscape in 2026 looks nothing like it did even three years ago. Two new disease-modifying therapies reached the market in 2024, a once-promising drug was pulled for safety concerns in 2025, and a first-of-its-kind anti-pruritus treatment is days away from an FDA decision. For the more than 100,000 Americans living with PBC, and for the healthcare providers who treat them, these developments demand attention and informed decision-making. What has not changed is the fundamental challenge of PBC: it remains a chronic, progressive autoimmune liver disease with no cure.
The new therapies offer better management of biochemistry and, potentially, of symptoms — but they are not magic bullets. Patients should work closely with hepatologists who are current on the latest approvals and withdrawals, ask direct questions about the evidence behind each drug, and understand that post-approval monitoring is not optional. The era of having just one drug and no choices was frustrating. The era of having multiple imperfect choices requires a different kind of engagement — more informed, more nuanced, and ultimately more empowering.
Frequently Asked Questions
What is linerixibat and when will it be available?
Linerixibat is an oral IBAT inhibitor developed by GSK that targets cholestatic pruritus in PBC. The FDA’s decision deadline is March 24, 2026. If approved, availability will depend on the commercial rollout by Alfasigma, which licensed worldwide rights from GSK in a deal worth up to $690 million.
How is linerixibat different from other PBC drugs?
Unlike UDCA, elafibranor, and seladelpar — which target liver disease progression through biochemical markers — linerixibat specifically targets the severe itching caused by bile acid accumulation. It would be the first FDA-approved drug designed to treat PBC-related pruritus rather than slow the underlying disease.
Why was Ocaliva pulled from the market?
The FDA identified 20 cases of serious liver injury between 2021 and 2024, including 7 liver transplants and 6 liver-related deaths, some in patients without cirrhosis. Intercept Pharmaceuticals voluntarily withdrew the drug in September 2025 at the FDA’s request, and it was officially removed from the U.S. market on November 14, 2025.
What are the main side effects of linerixibat?
In the GLISTEN trial, 61% of patients experienced diarrhea (vs. 18% on placebo) and 18% had abdominal pain (vs. 3% on placebo). About 7% of patients discontinued treatment due to gastrointestinal side effects. Patients should discuss with their doctors whether the potential itch relief justifies the GI side effect risk.
Are the 2024 PBC drug approvals considered final?
No. Both elafibranor (Iqirvo) and seladelpar (Livdelzi) received accelerated approval based on biochemical surrogate endpoints. Confirmatory trials must still demonstrate improvement in survival or prevention of liver decompensation. If those trials fail, the approvals could theoretically be reconsidered.
How common is PBC and who is most affected?
An estimated 105,506 adults in the United States have PBC, with a prevalence of about 40.9 per 100,000 persons. Women are affected at nearly four times the rate of men, with a prevalence of approximately 58 per 100,000 women compared to 15 per 100,000 men.
